Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Mar 30, 2018- First step to making FYCOMPA available for children, underscoring Eisai's commitment to epilepsy care for patients of all ages
Eisai Inc. announced today that it has submitted a supplemental New Drug Application (sNDA) for priority review to the U.S. Food and Drug Administration (FDA) for its antiepileptic drug FYCOMPA®...
-
Mar 7, 2018
Eisai Co., Ltd. (CEO: Haruo Naito, "Eisai") and Purdue Pharma L.P. (President and CEO: Craig Landau, "Purdue Pharma") today announced positive topline results from multiple studies of lemborexant,...
-
Feb 15, 2018
Eisai Inc. announced today that the positive results of a Phase 3 study (REFLECT study, Study 304) of its in-house discovered and developed anticancer agent lenvatinib mesylate (marketed as...
-
Feb 5, 2018
Eisai Inc. today announced the publication of results from a subgroup analysis of the pivotal Phase 3 study comparing eribulin mesylate (marketed as Halaven® Injection) with dacarbazine in...
-
Jan 30, 2018
Eisai Inc. and Boston University School of Medicine have formed a research collaboration to study the effects of Alzheimer's disease-associated genetic variants on the behavior of brain cells,...
-
Jan 19, 2018- Results of tumor response assessments by blinded independent imaging review using both mRECIST and RECIST v1.1 criteria to be presented today at the Gastrointestinal Cancers Symposium
Eisai Inc. announced today results from the independent imaging review (IIR) of the REFLECT study (Study 304), a Phase 3 trial evaluating lenvatinib (marketed as Lenvima®), the company's multiple...
-
Jan 9, 2018
Eisai Co., Ltd. and Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that they received Breakthrough Therapy Designation from the U.S. Food and Drug...
-
Dec 8, 2017- Results of this combination study were presented in a Spotlight Session (Spotlight Session 6: PD6-13) on December 7
Eisai Inc. today announced updated results of ENHANCE 1, a Phase 1b/2 trial investigating eribulin mesylate (marketed as HALAVEN®, "eribulin"), in combination with the Merck & Co., Inc.,...
-
Dec 6, 2017seizures and healthcare utilization associated with perampanel therapy
Eisai Inc. presented eight posters on perampanel (marketed as FYCOMPA® CIII) at the American Epilepsy Society (AES) Annual Meeting in Washington, D.C. The poster presentations included analyses...
Dec 5, 2017Tools now available to help adolescents with epilepsy transition to the adult health care system underscoring Eisai's leadership and commitment to the epilepsy communityThe Child Neurology Foundation (CNF) and Eisai today announced the availability of original resources aimed at helping those living with epilepsy navigate and simplify the transition from their...